CORRESP Filing
Caris Life Sciences, Inc.
Date: June 13, 2025 · CIK: 0002019410 · Accession: 0001104659-25-059442
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-287551
Letter
June 13, 2025
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-6010
Attention: Lauren Nguyen
Juan Grana
Michael Fay
Tayyaba Shafique
Re: Caris Life Sciences, Inc.
Registration Statement on Form S-1, as amended
File No. 333-287551
Acceleration Request
Requested Date: June 17, 2025
Requested Time: 4:00 P.M. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the " Act "), we, as representatives of the several underwriters, hereby join in the request of Caris Life Sciences, Inc. (the " Company ") for acceleration of the effective time of the above-referenced Registration Statement, requesting effectiveness as of 4:00 P.M., Eastern Time, on June 17, 2025, or at such later time as the Company or its outside counsel, Latham & Watkins LLP, may request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission.
Pursuant to Rule 460 under the Act, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.
We, the undersigned, as representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
[Signature Page Follows]
Very truly yours,
BOFA SECURITIES, INC.
Show Raw Text
CORRESP 1 filename1.htm June 13, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Lauren Nguyen Juan Grana Michael Fay Tayyaba Shafique Re: Caris Life Sciences, Inc. Registration Statement on Form S-1, as amended File No. 333-287551 Acceleration Request Requested Date: June 17, 2025 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended (the " Act "), we, as representatives of the several underwriters, hereby join in the request of Caris Life Sciences, Inc. (the " Company ") for acceleration of the effective time of the above-referenced Registration Statement, requesting effectiveness as of 4:00 P.M., Eastern Time, on June 17, 2025, or at such later time as the Company or its outside counsel, Latham & Watkins LLP, may request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Pursuant to Rule 460 under the Act, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement. We, the undersigned, as representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. [Signature Page Follows] Very truly yours, BOFA SECURITIES, INC. J.P. MORGAN SECURITIES LLC GOLDMAN SACHS & CO. LLC CITIGROUP GLOBAL MARKETS INC. As representatives of the underwriters BOFA SECURITIES, INC. By: /s/ Michael Liloia Name: Michael Liloia Title: Director J.P. MORGAN SECURITIES LLC By: /s/ David Ke Name: David Ke Title: Managing Director GOLDMAN SACHS & CO. LLC By: /s/ Lyla Bibi Maduri Name: Lyla Bibi Maduri Title: Managing Director CITIGROUP GLOBAL MARKETS INC. By: /s/ Tai Hah Name: Tai Hah Title: Global Head of MedTech [Signature Page to Underwriters' Acceleration Request]